Does REPLIGEN CORP have an economic moat?

Based on its FY2025 SEC filings, the Moat Index scores REPLIGEN CORP (RGEN) 52.1 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 85, returns on capital 11, balance-sheet safety 56, capital discipline 60.

Is RGEN stock trading below its intrinsic value?

Against a deliberately conservative owner-earnings model (9% discount rate, 0% assumed growth, capped at 4%), estimated intrinsic value is $20.54 per share versus a recent price of $147.25 — 617% above value. This is an educational estimate computed from primary SEC filings, not investment advice.

How has RGEN's Moat Score changed over time?

The record logs 3 readings since Jul 17, 2026; the latest reads 52.1 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

The Moat Index

REPLIGEN CORP

RGEN · Healthcare · $8.3B mkt cap · FY2025 filings · Shallow moat ·

Doesn't clear the bar

Shallow moat

The four filters

Pricing power85

Median gross margin 55.2% over 10y, stable.

Returns on capital11

Median ROIC 5.2%, above the 9% hurdle in 30% of years.

Balance-sheet safety56

Net cash position — no leverage risk.

Capital discipline60

Owner earnings +26.3%/yr, share count growing (dilution).

Margin of safety

Above valueOn sale

617% above value

Owner earnings (normalized): $104.1M
Est. intrinsic value / share: $20.54
Recent price: $147.25
Discount to value: 617% above value

Conservative model: 9% discount rate, 0% assumed growth (capped at 4%), maintenance capex ≈ min(capex, D&A).

17 years of fundamentals

The business, in plain English

REPLIGEN CORP booked $738.3M of revenue in FY2025 in the Healthcare sector and kept 52.3% of it as gross profit — a solid-margin business by that measure. After every other cost, 6.6% of each revenue dollar reached the bottom line.

Across the filed record, revenue grew from $21.0M (FY2010) to $738.3M (FY2025) — about 26.8% a year compounded over 15 years.

It earned 2.1% on invested capital in FY2025, with a median of 7.1% across 16 filed years. The Returns on Capital filter above scores it 11/100.

The balance sheet carried $542.2M of total debt in FY2025 against $104.1M of owner earnings — roughly 5.2 years of owner earnings to retire it all. Balance-Sheet Safety scores it 56/100.

The share count rose 83.4% between FY2011 and FY2025 — existing owners have been diluted over the record. Capital Discipline scores it 60/100.

Put together: Pricing Power is the strongest of the four filters (85/100) and Returns on Capital the weakest (11/100), which is how RGEN lands at 52/100 — a Shallow moat.

This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.

RevenueSales, as filed$738.3M FY2025

Gross marginRevenue kept after cost of goods52.3% FY2025

Return on invested capitalOperating profit on the capital employed2.1% FY2025

Owner earningsCash an owner could take out$104.1M FY2025

Gaps in a line mean that item isn’t in RGEN’s filings for that year — the series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.

Moat Score history

Moat Score over timeLast scored reading of each day, on the 0–100 scale52.1 / 100

Score history begins Jul 17, 2026 — the record builds from here and can’t be backfilled.

Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars

None yet — RGEN has read Shallow moat for every logged capture since Jul 17, 2026.

Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.

Healthcare context

#107 of 440 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

#105ANIK Anika Therapeutics, Inc.52.6 out of 100, Shallow moatShallow moat
#106MRVI Maravai LifeSciences Holdings, Inc.52.2 out of 100, Shallow moatShallow moat
#108CDIX Cardiff Lexington Corporation51.1 out of 100, Shallow moatShallow moat
#109PBYI PUMA BIOTECHNOLOGY, INC.50.5 out of 100, Shallow moatShallow moat

Compare RGEN with its nearest peers →All Healthcare companies on the Index →

Common questions about RGEN

Does REPLIGEN CORP have an economic moat?: Based on its FY2025 SEC filings, the Moat Index scores REPLIGEN CORP (RGEN) 52.1 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 85, returns on capital 11, balance-sheet safety 56, capital discipline 60.
Is RGEN stock trading below its intrinsic value?: Against a deliberately conservative owner-earnings model (9% discount rate, 0% assumed growth, capped at 4%), estimated intrinsic value is $20.54 per share versus a recent price of $147.25 — 617% above value. This is an educational estimate computed from primary SEC filings, not investment advice.
How has RGEN's Moat Score changed over time?: The record logs 3 readings since Jul 17, 2026; the latest reads 52.1 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

Embed this score on your site

One iframe, no script. The badge shows RGEN’s live Moat Score, updates itself as new filings are scored, and links back here. How it works.

<iframe
  src="https://buylikebuffett.com/embed/RGEN"
  width="340" height="150" style="border:0"
  title="RGEN Moat Score — The Moat Index"
  loading="lazy"></iframe>

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell RGEN. See the disclaimer.